Update on Menopause

Here’s the latest guidance on the safe use of menopausal hormone therapy, from an expert in the field.

Andrew M. Kaunitz, MD

As new options for managing menopausal symptoms emerge, so do data on their efficacy and safety. Highlights in this article include:
- Long-term follow-up data from the Women’s Health Initiative (WHI) on the benefits and risks of hormone therapy (HT) (this page)
- Guidance from the American College of Obstetricians and Gynecologists (ACOG) on the management of menopausal symptoms, including advice on individualization of therapy for older women (page 48)
- A randomized trial of testosterone enanthate to improve sexual function among hysterectomized women (page 49)
- A Swedish study on concomitant use of HT and statins (page 50).

“Critical Window” HT Timing Is Revealed


After the initial 2002 publication of findings from the WHI trial of women with an intact uterus who were randomized to receive conjugated equine estrogens and medroxyprogesterone acetate or placebo, prominent news headlines claimed that HT causes myocardial infarction (MI) and breast cancer. As a result, millions of women worldwide stopped taking HT. A second impact of the report: Many clinicians became reluctant to prescribe HT.

Although it generated far less media attention, research published in the Journal of the American Medical Association in October 2013 details findings from a 13-year follow-up of WHI HT clinical trial participants and better informs clinicians and our patients about HT’s safety profile.

During the WHI intervention phase, absolute risks were modest

Although HT was associated with a multifaceted pattern of benefits and risks in both the estrogen-progestin therapy (EPT) and estrogen-only therapy (ET) arms of the WHI, absolute risks, as reflected in an increase or decrease in the number of cases per 10,000 women treated per year, were modest.

For example, the hazard ratio (HR) for coronary heart disease (CHD)

What this evidence means for practice

Long-term follow-up of women who participated in the WHI clarifies the benefit-risk profile of systemic HT, underscoring that the benefit-risk ratio is greatest in younger menopausal women.

Because the safety of HT is greater in women nearer the onset of menopause, as well as in those at lower baseline risk for cardiovascular disease (CVD), individualized risk assessment may improve the benefit-risk profile and safety of HT. One approach to decision-making for women with bothersome menopausal symptoms is the MenoPro app, a free mobile app from the North American Menopause Society, with modes for both clinicians and patients.

Andrew M. Kaunitz is University of Florida Research Foundation Professor and Associate Chairman, Department of Obstetrics and Gynecology, at the University of Florida College of Medicine–Jacksonville. He reports that he receives grant or research support from Bayer and Therapeutics MD and is a consultant to Actavis and Bayer. This article originally appeared in OBG Management (2015;27[6]:37-40, 42, 43).
during the intervention phase, during which participants were given HT or placebo (mean 5.2 years for EPT and 6.8 years for ET) was 1.18 in the EPT arm (95% confidence interval [CI], 0.95-1.45) and 0.94 in the ET arm (95% CI, 0.78-1.14). In both arms, women given HT had reduced risk for vasomotor symptoms, hip fractures, and diabetes, and increased risk for stroke, venous thromboembolism (VTE), and gallbladder disease, compared with women receiving placebo.

The results for breast cancer differed markedly between arms. During the intervention period, an elevated risk was observed with EPT while a borderline reduced risk was observed with ET. Among participants older than 65 at baseline, the risk for cognitive decline was increased in the EPT arm but not in the ET arm.

### Post intervention, most risks and benefits attenuated
An elevation in the risk for breast cancer persisted in the EPT arm (cumulative HR over 13 years, 1.28; 95% CI, 1.11-1.48). In contrast, in the ET arm, a significantly reduced risk for breast cancer materialized (HR, 0.79; 95% CI, 0.65-0.97) (see Table).

To put into perspective the elevated risk for breast cancer observed among women randomly allocated to EPT, the attributable risk is less than 1 additional case of breast cancer diagnosed per 1,000 EPT users annually. Another way to frame this elevated risk: An HR of 1.28 is slightly higher than the HR conferred by consuming one glass of wine daily and lower than the HR noted with two glasses daily.¹

Overall, results tended to be more favorable for ET than for EPT. Neither type of HT affected overall mortality rates.

### Age differences come to the fore
The WHI findings demonstrate a lower absolute risk for adverse events with HT in younger versus older participants. In addition, age and time since menopause appeared to affect many of the HRs observed in the trial.

In the ET arm, more favorable results for all-cause mortality, MI, colorectal cancer, and the global index (CHD, invasive breast cancer, pulmonary embolism, colorectal cancer, and endometrial cancer) were observed in women ages 50 to 59 at baseline. In the EPT arm, the

### Further Evidence That HT Is Safe When Initiated Soon After Menopause

In Finland, all deaths are recorded in a national register, in which particular attention is paid to accurately classifying those thought to result from coronary heart disease (CHD). In addition, since 1994, all HT users have been included in a national health insurance database, enabling detailed assessment of HT use and coronary artery disease. Investigators assessed CHD mortality from 1995 to 2009 in more than 290,000 HT users, comparing them with the background population matched for year and age.

Use of HT was associated with reductions in the CHD mortality rate of 18% to 29% (for ≤ 1 year of use) and 43% to 54% (for 1-8 years of use). Similar trends were noted for EPT and ET. The HT-associated protection against CHD mortality was more pronounced in users younger than 60.

Tuomikoski and colleagues concluded, and I concur, that the observational nature of their data does not allow us to recommend HT specifically to prevent CHD. Nonetheless, these findings, along with long-term follow-up data from the WHI, make the case that, for menopausal women who are younger than 60 or within 10 years of the onset of menopause, clinicians may consider initiating HT to treat bothersome vasomotor symptoms, a safe strategy with respect to CHD.

—Andrew M. Kaunitz, MD

---

### Table: Hazard Ratios for Hormone Therapy After 13-year Follow-up in the WHI*

<table>
<thead>
<tr>
<th>Hazard ratio</th>
<th>Estrogen-progesterin therapy</th>
<th>Estrogen-only therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>0.99</td>
<td>0.99</td>
</tr>
<tr>
<td>Age 50–59</td>
<td>0.88</td>
<td>0.78</td>
</tr>
<tr>
<td>Age 60–69</td>
<td>0.99</td>
<td>1.02</td>
</tr>
<tr>
<td>Age 70–79</td>
<td>1.04</td>
<td>1.06</td>
</tr>
<tr>
<td>Global index</td>
<td>1.06 (P = .05)</td>
<td>1.02</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>1.28 (P &lt; .05)</td>
<td>0.79 (P &lt; .05)</td>
</tr>
</tbody>
</table>

*All P values > .05 (not statistically significant) unless stated otherwise.
risk for MI was elevated only in women more than 10 years past the onset of menopause at baseline. Both HT regimens, however, were associated with increased risk for stroke, VTE, and gallbladder disease.

EPT increased the risk for breast cancer in all age-groups. However, the lower absolute risks for adverse events, and generally more favorable HRs for many outcomes, in younger women resulted in substantially lower rates of adverse events attributable to HT in the younger age-group, compared with older women.

As far as CHD is concerned, the impact of age (or time since menopause) on the vascular response to HT in women and in nonhuman models has generated support for a “critical window” or timing hypothesis, which postulates that estrogen reduces the development of early stages of atherosclerosis while causing plaque destabilization and other adverse effects when advanced atherosclerotic lesions are present. Recent studies from Scandinavia provide additional support for this hypothesis (see the sidebar, page 47).

REFERENCE
(0.45 mg) with the selective estrogen receptor modulator (SERM) bazedoxifene (20 mg).

• The oral SERM ospemifene (60 mg) is effective for relief of dyspareunia associated with vulvovaginal atrophy (also known as genitourinary syndrome of menopause).

• Paroxetine mesylate (7.5 mg) is the only FDA-approved nonhormonal formulation for management of vasomotor symptoms and is dosed lower than regimens used to treat psychiatric conditions.

Steer patients clear of compounded formulations

Every week, I encounter patients who have recently visited clinicians who prescribe and sell compounded bioidentical hormones. In addressing this issue, ACOG provides a useful service to women and their clinicians:

“Because of a lack of FDA oversight, most compounded preparations have not undergone any rigorous clinical testing for either safety or efficacy, so the purity, potency, and quality of compounded preparations are a concern. In addition, both underdosing and overdosing are possible because of variable bioavailability and bioactivity. Evidence is lacking to support superiority claims of compounded bioidentical hormones over conventional menopausal HT.... Conventional HT is preferred, given the available data.”

REFERENCE


Testosterone Improves Parameters of Sexual Function


No formulation of testosterone is approved by the FDA for use in women. Nonetheless, in the United States, many menopausal women hoping to boost their sexual desire are prescribed, off-label, testosterone formulations indicated for use in men, as well as compounded formulations.¹

Investigators randomly allocated women who had undergone hysterectomy to 12 weeks of transdermal estradiol followed by 24 weekly intramuscular injections of placebo or testosterone enanthate at doses of 3.0, 6.0, 12.5, or 25.0 mg while continuing estrogen. At the outset of the trial, all women had serum free testosterone levels below the range for healthy premenopausal women.

Among the 62 women who received testosterone, serum testosterone levels increased in a dose-related fashion. Among those allocated to the highest dose, serum total testosterone levels at 24 weeks were five to six times higher than values in healthy premenopausal women. Compared with women who received placebo, those who received the highest testosterone dose had better measures of sexual desire, arousal, and frequency of sexual activity. Excess hair growth was significantly more common in women who received the two highest doses of testosterone.

REFERENCE

Is HT Safe in Statin Users?

Since the initial publication of findings from the WHI, clinicians have been cautioned not to prescribe menopausal HT in women at elevated risk for CVD. In this study from Sweden, investigators enrolled women ages 40 to 74 who initiated statin use between 2006 and 2007 due to known CVD (secondary prevention) or in the absence of known CVD (primary prevention). Women were followed for a mean of four years after beginning statins, until the end of 2011.

Of 40,958 statin users, 7% used HT (mean age of HT users and nonusers was 61 and 62, respectively). Overall, 70% of statin use was for primary prevention. Deaths from CVD occurred in 5 and 18 patients per 10,000 person-years among HT users and nonusers, respectively (HR, 0.38). All-cause mortality occurred in 33 and 87 patients per 10,000 person-years among HT users and nonusers, respectively (HR, 0.53). These reduced risks for mortality noted in women who used concomitant statins achieved statistical significance. Whether statins were used for primary or secondary prevention, the incidence of cardiovascular events was similar in HT users and nonusers.

Why these findings diverge from those of the WHI
The findings of this large prospective cohort study are consistent with findings from other large observational studies—though they diverge from WHI findings. As Berglind and colleagues note, few WHI participants used statins at baseline. Also in contrast with the WHI, in which all HT was based on conjugated estrogen, all HT users in this Swedish study used oral or transdermal estradiol, as conjugated estrogen is not available in Sweden (and appears to be associated with an elevated risk for CVD, compared with other estrogens1).

REFERENCE

What this evidence means for practice
This important study provides strong evidence that, for menopausal women with bothersome vasomotor symptoms or an elevated risk for osteoporosis, concomitant use of statins should not be considered a contraindication to HT.